Private placement financing concluded by Revive Therapeutics
Revive Therapeutics Secures Funding for Ongoing Programmes
Revive Therapeutics, a specialty life sciences company focused on developing innovative therapeutics for critical medical needs, has announced the successful closure of a second tranche of a private placement. The company raised gross proceeds of $91,400 in September 2025.
The private placement was for 4,352,381 units at a price of $0.021 per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one common share at an exercise price of $0.05 for 36 months.
Michael Frank, the Chief Executive Officer of Revive Therapeutics Ltd., spearheads the company's operations. You can reach him via telephone at 1 888 901 0036, email at [email protected], or on the company's website at www.revivethera.com.
The funds raised will be utilised for working capital and payment of certain trade payables. It is important to note that the forward-looking information contained in this press release is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Revive Therapeutics is not obligated to update or revise any forward-looking information, except as required by applicable securities laws.
The forward-looking information is based on reasonable assumptions made by Revive at the date of the press release. The company is currently exploring the potential of Bucillamine for infectious diseases and medical countermeasures, and is vigorously advancing its Psilocybin and molecular hydrogen therapeutic programs.
Investors are encouraged to review the risk factors related to Revive Therapeutics, which are disclosed under the heading "Risk Factors" in the Company's management's discussion and analysis for the three and nine months ended March 31, 2025. This document is available on the Company's profile at www.sedarplus.ca.
All securities issued are subject to a hold period of four months and one day expiring on January 19, 2026. The Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Read also:
- Potential Consequences of Dismantling FEMA Vary Across States
- Railway line in Bavaria threatened by unstable slope - extensive construction site at risk
- Wind Farm Controversy on the Boundary of Laois and Kilkenny
- Puerto Rico's Climate Lawfare Campaign experiences another setback with the dismissal of its deals.
